Please login to the form below

Not currently logged in
Email:
Password:

PPD set to conduct more clinical trials in Germany

Signs research collaboration with Charité–Universitätsmedizin Berlin

PPDContract research organisation PPD aims to increase the number of clinical trials it conducts in Germany as part of a newly-signed strategic collaboration with Charité–Universitätsmedizin Berlin.

The deal will also see the CRO and the teaching hospital's clinical trials management unit work together to improve patient access to commercial clinical research and accelerate the development of new medicines.

PPD is hoping that by working with the Charité it can shorten study start-up times and maximise the number of patients recruited for a wide range of phase 1-4 trials across multiple therapeutic areas.

The US-headquartered CRO also sees benefits coming from improvements in the quality of data generated and the standard of training for site staff.

Roger Newbery, PPD's vice president of clinical management for Europe, Middle East and Africa, said: “Germany's abundance of intellectual and technical resources, coupled with the ongoing advances that have streamlined the clinical research process, make the country extremely attractive for clinical research.

“We welcome the opportunity to strengthen our relationship with a world-class treatment facility that is one of our most experienced and most frequently used clinical research sites globally.”

The collaboration builds upon PPD's long-standing relationship with the Charité, which is one of Europe's largest university hospitals and maintains more than 100 clinics and institutes within 17 Charité Centers at its four campuses.

Article by
Dominic Tyer

24th February 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics